Clivatuzumab tetraxetan

Names

[ Name ]:
Clivatuzumab tetraxetan

Biological Activity

[Description]:

Clivatuzumab tetraxetan (IMMU107) is a humanized anti-MUC1 monoclonal antibody. Clivatuzumab tetraxetan shows anti-tumor activity. Clivatuzumab tetraxetan has the potential for the research of metastatic pancreatic cancer[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[In Vivo]

Clivatuzumab tetraxetan (50, 100 µg; i.v.; once 以剂量依赖性方式减小肿瘤体积并增加小鼠的中位生存期[2]。 Animal Model: Nude mice (Capan-1 tumors)[2] Dosage: 50, 100 µg Administration: I.v.; once Result: Significantly decreased tumor volume in a dose-dependent manaer and increased the median survival to 13 weeks.

[References]

[1]. Shimizu M, et al. Thrombin-induced platelet aggregation -effect of dabigatran using automated platelet aggregometry. Platelets. 2020;31(3):360-364.

[2]. Sharkey RM, et al. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther. 2011 Jun;10(6):1072-81.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.